Beigene, Ltd. - Net Worth and Insider Trading

Beigene, Ltd. Net Worth

The estimated net worth of Beigene, Ltd. is at least $2 Million dollars as of 2024-11-29. Beigene, Ltd. is the 10% Owner of Leap Therapeutics Inc and owns about 734,844 shares of Leap Therapeutics Inc (LPTX) stock worth over $2 Million. Details can be seen in Beigene, Ltd.'s Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Beigene, Ltd. has not made any transactions after 2021-09-24 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Beigene, Ltd.

To

Beigene, Ltd. Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Beigene, Ltd. owns 1 companies in total, including Leap Therapeutics Inc (LPTX) .

Click here to see the complete history of Beigene, Ltd.’s form 4 insider trades.

Insider Ownership Summary of Beigene, Ltd.

Ticker Comapny Transaction Date Type of Owner
LPTX Leap Therapeutics Inc 2021-09-24 10 percent owner

Beigene, Ltd. Latest Holdings Summary

Beigene, Ltd. currently owns a total of 1 stock. Beigene, Ltd. owns 734,844 shares of Leap Therapeutics Inc (LPTX) as of September 24, 2021, with a value of $2 Million.

Latest Holdings of Beigene, Ltd.

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
LPTX Leap Therapeutics Inc 2021-09-24 734,844 2.92 2,145,744

Holding Weightings of Beigene, Ltd.


Beigene, Ltd. Form 4 Trading Tracker

According to the SEC Form 4 filings, Beigene, Ltd. has made a total of 1 transactions in Leap Therapeutics Inc (LPTX) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Leap Therapeutics Inc is the acquisition of 254,380 shares on September 24, 2021, which cost Beigene, Ltd. around $7 Million.

Insider Trading History of Beigene, Ltd.

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Beigene, Ltd. Trading Performance

GuruFocus tracks the stock performance after each of Beigene, Ltd.'s buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Beigene, Ltd. is -17.37%. GuruFocus also compares Beigene, Ltd.'s trading performance to market benchmark return within the same time period. The performance of stocks bought by Beigene, Ltd. within 3 months outperforms 0 times out of 1 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Beigene, Ltd.'s insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Beigene, Ltd.

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
0 out of 1 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -18.49 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -20.5 LIMIT LIMIT LIMIT LIMIT LIMIT

Beigene, Ltd. Ownership Network

Ownership Network List of Beigene, Ltd.

No Data

Ownership Network Relation of Beigene, Ltd.

Insider Network Chart

Beigene, Ltd. Owned Company Details

What does Leap Therapeutics Inc do?

Who are the key executives at Leap Therapeutics Inc?

Beigene, Ltd. is the 10 percent owner of Leap Therapeutics Inc. Other key executives at Leap Therapeutics Inc include Chief Scientific Officer Jason Baum , VP & Head of Reg Affairs/Qual Christine Granfield , and 10 percent owner Perceptive Life Sciences Master Fund Ltd .

Leap Therapeutics Inc (LPTX) Insider Trades Summary

In summary, during the past 3 months, insiders sold 0 shares of Leap Therapeutics Inc (LPTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Leap Therapeutics Inc (LPTX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.

Leap Therapeutics Inc (LPTX)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Leap Therapeutics Inc Insider Transactions

No Available Data

Beigene, Ltd. Mailing Address

Above is the net worth, insider trading, and ownership report for Beigene, Ltd.. You might contact Beigene, Ltd. via mailing address: C/o Mourant Governance Services (cayman), 94 Solaris Avenue, Camana Bay, Grand Cayman E9 Ky1-1108.

Discussions on Beigene, Ltd.

No discussions yet.